Managing Myeloma ASH 2015 Meeting Highlights: The New Era of Precision Medicine for Multiple Myeloma

Please Log In or Register to continue.

Release Date: January 08, 2016
Expiration Date: January 08, 2017

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Significant progress has been made in both the understanding of the underlying biology that leads to multiple myeloma (MM) disease progression and drug resistance as well as in prolonging the survival of patients with MM in the past decade and a half. Contributing to the improved prognosis for the majority of MM patients has been the rapid translation of clinical advancements into practice, including improved diagnostic, staging and risk assessment criteria, the introduction of highly effective agents which can be provided in rational combination regimens, the use of HDT-ASCT in patients that can tolerate this approach, the development of uniform criteria to monitor responses to treatment, and evolving risk-adaptive management and supportive care strategies which also contribute to improved quality of life for patients. Consequently, MM is transitioning from a malignancy that was once considered to be universally fatal to one more characteristic of a chronic disease. Nevertheless, challenges do remain. The majority of patients will eventually relapse, and a small but significant number of patients have high-risk disease with corresponding poor prognosis for which most therapies have proven to be less effective in providing benefit. These clinical barriers are being addressed through ongoing clinical trials. The recent pace of MM clinical development and changes to standard-of-care treatment and management approaches often exceeds the ability of community-based oncology physicians and their allied health care team members to effectively and efficiently translate these new advances into practice. Indeed, between 2000 and 2010 there were three new drugs approved for the treatment of MM and three updates to the indications for drugs; in the years 2010 to 2014, two new drugs were approved and two extended indications for already approved drugs were granted. Presenting the most expansive increase in therapeutics in the history of MM care, in 2015 four new drugs have been approved, including a first-in-class HDAC inhibitor earlier in the year and three more in the last two weeks of November 2015, including a first-in-class immunotherapy and a second immunotherapeutic drug quite different from the first and the first orally administered proteasome inhibitor. Furthermore, updates to International Myeloma Working Group (IMWG) guideline recommendations in the past year affect nearly every aspect of MM management and care contributing to what is considered the new paradigm in management – earlier intervention for active multiple myeloma management, more accurate prognostic assessment and continuous therapy.

Join team Managing Myeloma world experts as they discuss the most significant clinical findings from the 2015 annual American Society of Hematology (ASH) meeting in Orlando, Florida. This year’s meeting may be remembered as one of the most significant in the modern era of MM care. Advances impacting practice today include a new oral proteasome inhibitor, the introduction of immunotherapeutics, data regarding new regimens, the role of upfront transplant versus delayed transplant, and approaches to assessing disease response and minimum residual disease.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Recognize key clinical studies as presented at the 2015 American Society of Hematology Meeting (ASH) 57th Annual Meeting and Exhibition which may impact practice
  • Recall efficacy, safety, and trial limitations that affect the interpretation of specific multiple myeloma studies as presented at the 2015 ASH annual meeting which may impact current practice

Agenda

New Era of Precision Medicine for Multiple Myeloma: Insights Regarding the Role of the Immune System in Myeloma Disease Progression and Treatment – Sagar Lonial, MD

Newly Diagnosed Myeloma in Transplant Eligible Patients in an Era of Precision Medicine: Seeking Standard of Care – Jatin J. Shah, MD

Newly Diagnosed Myeloma in Transplant Ineligible Patients: Seeking Standard of Care in an Era of Precision Medicine
– Robert Z. Orlowski, MD, PhD

Extending Options in Relapsed Refractory Disease in an Era of Precision Medicine for Multiple Myeloma
– Philippe Moreau, MD

Immunotherapy in an Era of Precision Medicine for Multiple Myeloma Patient Care
– Paul G. Richardson, MD

Instructions for Participation and Credit
This activity is eligible for credit through January 8, 2017. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is a professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University where he is also the vice chair of clinical affairs, as well as director of the Translational Research for the B-Cell Malignancy Program.

He is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. In addition, he serves on the editorial board of the Journal of Clinical Oncology, Leukemia, and is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and also serves as an invited and ad hoc reviewer for several publications including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others. Dr. Lonial has authored/coauthored over 200 publications and recently was awarded the Celgene ‘Young Investigator’ Award, the MMRF ‘Top 15 Innovator’ Award, and the MMRC ‘Center of the Year’ award.

Dr. Lonial’s research interest is on combination therapy in B-cell malignancies focusing on myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His clinical interests include evaluating the combination of new molecular targeted agents for B-cell tumors as well as target discovery and validation.

Paul G. Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, and was chief resident at the Royal Marsden Hospital, London. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, he joined Dana-Farber Cancer Institute (DFCI). Dr. Richardson spent five years with the Solid Tumor Autologous Marrow Program, completed a medical residency at Beth Israel Hospital, and joined DFCI’s Jerome Lipper Multiple Myeloma Center, becoming clinical director and most recently, clinical program leader and director of clinical research.

Robert Z. Orlowski, MD, PhD
Professor, Chair Ad Interim
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Robert Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University, St. Louis School of Medicine. Dr. Orlowski is a professor and Chair Ad Interim in the Department of Lymphoma/Myeloma, and professor in the Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Board-certified in internal medicine and medical oncology, Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy with a focus on the pathogenesis of oncologic disease and mechanisms of action of chemotherapeutics. In addition, he is a reviewer for several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and The New England Journal of Medicine. His clinical research efforts focus on novel clinical trials for patients with hematologic malignancies.

Jatin J. Shah, MD
Associate Professor
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Jatin Shah received his medical degree from Ohio State University College of Medicine, Columbus, Ohio. He completed an internship and residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr. Shah is an associate professor and associate program director of the malignant hematology fellowship, as well as director of myeloma clinical and translational research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, Houston.

Dr. Shah holds board certification in hematology and oncology from the American Board of Internal Medicine. He is a member of the American Medical Association, American College of Physicians-American Society of Internal Medicine, American Society of Clinical Oncology, American Society of Hematology, American Association of Cancer Research, SWOG, and the International Myeloma Working Group. Dr. Shah is currently a reviewer for the British Journal of Haematology, Cancer, Leukemia, and The Oncologist. In addition he is principal investigator/co-investigator for numerous relapsed/refractory multiple myeloma studies and has published articles and abstracts in many peer-reviewed journals.

Philippe Moreau, MD
University Professor of Clinical Hematology
Nantes Faculty of Medicine
Hematology Department
University Hospital of Nantes
Nantes, France

Dr.  Philippe Moreau is head of the Hematology Department at the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment with high-dose therapy and novel agents. Dr. Moreau was appointed University Professor of Clinical Hematology at Nantes Faculty of Medicine in 2003.

As leading researcher in multiple myeloma, Dr. Moreau is head of the unit for early phase 1 and phase 2 trials in clinical hematology at the University Hospital of Nantes. Additionally, he was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris. Dr. Moreau is currently a member of the administration council of the Intergroupe Francophone du Myélome (IFM), and he was chairman from 2006 through 2009.

Dr. Moreau is widely published, with more than 300 per-reviewed articles and reviews that have appeared in high impact factor journals including The New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, and Blood. In addition, he is a member of the editorial board of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal and is a frequently invited speaker at international hematologic oncology meetings.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-16-063-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: Program Number: 16-063-026

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, Onyx, Sanofi, and Takeda Oncology.

Dr. Jatin Shah has received honoraria related to formal advisory activities from Array BioPharma, Celgene Corporation, FORMA Therapeutics, Inc., Novartis AG, Onyx, and Takeda Oncology. He has received grant support related to research activities from Array BioPharma, Bristol-Myers Squibb Company, Celgene, Novartis, Onyx, and Takeda Oncology.

Dr. Robert Orlowski has received honoraria related to formal advisory activities from Array BioPharma, Bristol-Myers Squibb Company, Celgene Corporation, FORMA Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Takeda Oncology, and Onyx. He has received grant support related to research activities from Array BioPharma, Bristol-Myers Squibb, Celgene, Spectrum Pharmaceuticals, Inc., Takeda Oncology, and Onyx.

Dr. Philippe Moreau has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, and Takeda Oncology.

Dr. Paul Richardson has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company, Celgene Corporation, Genmab A/S, Janssen Pharmaceuticals, Inc., Novartis AG, Onyx, and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Lonial has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Shah, Orlowski, Moreau, and Richardson have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Lonial has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Drs. Shah, Orlowski, Moreau, and Richardson have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.